Curacyte Overview
- Year Founded
-
1998
- Status
-
Out of Business
- Employees
-
15
- Latest Deal Type
-
Liquidation
Curacyte General Information
Description
Developer of advanced biopharmaceutics intended to treat acute and critical diseases. The company's advanced biopharmaceutics develops new medicines in the areas of hematology, antithrombosis, and oncology, enabling people to avail the new generation of drugs.
Contact Information
Website
www.curacyte.euCorporate Office
- C/o Dornbach GmbH
- Arnulfstraße 39
- 80636 Munich
- Germany
Corporate Office
- C/o Dornbach GmbH
- Arnulfstraße 39
- 80636 Munich
- Germany
Curacyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Bankruptcy: Liquidation | 30-Aug-2016 | Completed | Bankruptcy: Liquidation | |||
| 5. Later Stage VC | 29-Dec-2012 | Completed | Generating Revenue | |||
| 4. Grant | Completed | Generating Revenue | ||||
| 3. Secondary Transaction - Private | 30-Jun-2012 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series C) | 20-Dec-2005 | $37.3M | $76.2M | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Jan-2000 | $38.9M | $38.9M | Completed | Generating Revenue |
Curacyte Patents
Curacyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2008107176-A1 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | Inactive | 06-Mar-2007 | ||
| WO-2008077631-A1 | Substituted 5h-pyrimidol[5,4-b]indoles, method for the production thereof, and use thereof for treating non-solid malignant tumors of the blood-producing system | Inactive | 22-Dec-2006 | ||
| WO-2008049595-A1 | Trypsin-like serine protease inhibitors, and their preparation and use | Inactive | 24-Oct-2006 | ||
| WO-2008049595-A9 | Trypsin-like serine protease inhibitors, and their preparation and use | Inactive | 24-Oct-2006 | ||
| DE-102005044319-A1 | 2- (aminomethyl) -5-chloro-benzylamide derivatives and their use as inhibitors of coagulation factor xa | Inactive | 16-Sep-2005 | C07K5/06139 |
Curacyte Signals
Curacyte FAQs
-
When was Curacyte founded?
Curacyte was founded in 1998.
-
Where is Curacyte headquartered?
Curacyte is headquartered in Munich, Germany.
-
What is the size of Curacyte?
Curacyte has 15 total employees.
-
What industry is Curacyte in?
Curacyte’s primary industry is Therapeutic Devices.
-
Is Curacyte a private or public company?
Curacyte is a Private company.
-
What is Curacyte’s current revenue?
The current revenue for Curacyte is .
-
How much funding has Curacyte raised over time?
Curacyte has raised $85.4M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process